Dong-A ST announced on October 1 that Japanese chemical research institute SKK filed with the Japanese Ministry of Health, Labor and Welfare for permission to manufacture and sell DA-3880, a biosimilar for the treatment of anemia, whose production technology was transferred from Dong-A ST.DA-3880 is
GC Pharma, a major Korean biopharmaceutical company, is facing a further delay in winning U.S. approval on its blood derivatives IVIS-SN as it recently received a second Complete Response Letter (CRL) notification from the U.S. FDA.The company completed the submission of supplementary data in March
Samsung Electronics is taking steps to sell off a unit of its Medical Device Division.According to industry sources on September 19, Samsung Electronics held an employee briefing session presided over by Jeon Dong-soo, head of the Medical Device Division and president of Samsung Medison, on the plan
JLK Inspection (CEO Wontae Kim), a member company of the K-ICT Born2Global Centre, announced that its ischemic stroke diagnosis-supporting software JBS-01K has been first approved by the Ministry of Food and Drug Safety (MFDS) of South Korea as an AI-based class III computer-aided diagnosis system.C
In the second quarter of this year, Apple solidified its lead in the global smart watch market with a 41% share. Samsung Electronics’ market share plunged by 43% year on year to place sixth.According to Counterpoint Research, a global market research company, sales of global smart watches swelled 37
"Samsung Health," a health record management application for smartphone users from Samsung Electronics, surpassed 500 million downloads globally.However, the remote medical services that Samsung Health provides and are generally available in overseas countries are not provided in Korea. Korean smart
Andong City in North Gyeongsang Province is emerging as the center of the Korean vaccine industry.The provincial government has been seeking to create a medical cluster encompassing vaccine in Andong, Asian medicine in Gyeongsan, and accelerator-based new drugs in Pohang.In Andong, there are already
Medical equipment stocks has received a big boost from the government’s announcement that it would significantly ease regulations on medical devices and reduce the time it takes for new medical devices to enter the market. The beneficiaries of the government’s belated deregulation initiative are sto
Korean biotechnology companies are stepping up efforts to make a foray into the microbiome market. They are pushing to develop products that use microbes in the body to treat various diseases.The microbiome market is regarded as the next battlefield for biotechnology firms and pharmaceutical compani
A Korean research institute has succeeded in developing a blood preservative using an Antarctic microorganism for the first time in the world.The Ministry of Maritime Affairs and Fisheries said on June 27 that the Korea Polar Research Institute (KOPRI) will sign a technology transfer agreement with
Domestic pharmaceutical companies, which have been focusing on emerging countries such as Southeast Asia and South America, are stepping up efforts to advance into the US, the world's largest pharmaceutical market.According to industry reports on March 23, Green Cross Corp. recently established
Korea Ginseng Corporation (KGC) is stepping up marketing efforts for red ginseng products. The company has replaced the spokesmodel for “CheongKwanJang Everytime” with a new-generation figure and is diversifying cosmetics products loaded with red ginseng.The most popular red ginseng product made by
Korean pharmaceutical companies are expected to develop Cancer immunotherapy drugs within a few years because some Korean companies began to accumulate and develop related technologies.More intense competition is expected in the domestic market of cancer immunotherapy drugs called “third-generation
Celltrion Inc. and Samsung Bioepis Co. show a significant growth in the global biosimilar medicine market but see poor performance in the domestic market.According to industry sources on March 26, Celltrion posted 21.2 billion won (US$19.64 million) in sales in the domestic biosimilar market last ye
The National Research Foundation of Korea announced on March 12 that a research team led by Yonsei University professor Shim Woo-young developed a nanoparticle-based and high-sensitivity flexible pressure sensor.These days, a lot of attempts are being made for transparent and flexible wearable devic
According to industry sources on December 18, the number of domestic pharmaceutical and biotech companies that are seeking to develop cell therapy products has greatly increased. There are two primary concerns that domestic firms have. First of all, there is an outstanding boom in the development of
The Korean biotech industry joined competition to develop a chimeric antigen receptor-T cell (CAR-T) therapeutic drug called “the cancer drug of doctors’ dream.” CAR-T is a technology that allows T cells which are a kind of common immune cells in blood to selectively attack cancer cells after pinpoi
There are a growing number of patent applications for “bio-printing” technology which combines 3D printing with biotechnology to produce artificial organs. The reason is that donors are in shortage compared to need for organ donations and the negative side effects of existing organ transplants such
Morgan Stanley is dragging down Celltrion whose stock price is flying high. This is because Morgan Stanley is publishing negative outlook reports one after another while suggesting a target stock price half the current stock price. The securities industry is critical of Morgan Stanley as the global
South Korea is situated on the periphery of the global pharmaceutical industry map. The global drug market reached US$1.1 trillion (1,244 trillion won) as of last year, the South Korean market stood at 21.7 trillion won (US$19.19 billion), accounting for a 0.012 percent of the total. There are no So